CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2017—Roche announced the CE-IVD launch of Cobas HPV for use on the Cobas 6800/8800 Systems for cervical cancer screening. This HPV DNA assay gives laboratories the ability to run HPV DNA testing simultaneously with other previously released Cobas assays, including chlamydia and gonorrhea (CT/NG), HIV-1, HCV, HBV, CMV, and three next-generation assays for donor screening: the Cobas MPX, Cobas WNV, and Cobas HEV.
The fully automated Cobas 6800/8800 Systems provide fast turnaround times, high throughputs, and long walkaway times, giving laboratories the flexibility to adapt to changing testing demands.
Roche, +41 61 688 8888